Shares of XtalPi Holdings Ltd (02228), a provider of drug discovery and intelligent automation solutions, surged 18.21% on Wednesday as investors reacted positively to the company's plans for a share placement and its involvement in an AI integration project.
XtalPi announced a private placement of 342.3 million shares at HK$6.10 per share, aiming to raise around HK$2.09 billion (US$268.8 million). The proceeds will be used for research and development, product commercialization, and working capital purposes. The new shares represent 8.52% of the company's enlarged issued share capital.
Additionally, XtalPi's subsidiary Shenzhen Jingtai is partnering with state-owned Guangdong Hengjian Investment to advance the implementation of an "AI+" technology and industry integration innovation consortium project. The project focuses on "AI+ Robotic Automation" and aims to build AI research infrastructure for the future development of AI-based industries such as pharmaceuticals, new materials, new energy, and robotics in China's Greater Bay Area and globally.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。